307 related articles for article (PubMed ID: 26980598)
21. Tumor-specific up-regulation of the nonclassical class I HLA-G antigen expression in renal carcinoma.
Ibrahim EC; Guerra N; Lacombe MJ; Angevin E; Chouaib S; Carosella ED; Caignard A; Paul P
Cancer Res; 2001 Sep; 61(18):6838-45. PubMed ID: 11559559
[TBL] [Abstract][Full Text] [Related]
22. Multidimensional Analyses of Tumor Immune Microenvironment Reveal the Possible Rationality of Immunotherapy and Identify High Immunotherapy Response Subtypes for Renal Papillary Cell Carcinoma.
Wei B; Yu M; Yao J; Jiang M; An J; Yang J; Lin J; Zhao Y; Zhu Y
Front Immunol; 2021; 12():657951. PubMed ID: 34531849
[TBL] [Abstract][Full Text] [Related]
23. Failed immune responses across multiple pathologies share pan-tumor and circulating lymphocytic targets.
Monette A; Morou A; Al-Banna NA; Rousseau L; Lattouf JB; Rahmati S; Tokar T; Routy JP; Cailhier JF; Kaufmann DE; Jurisica I; Lapointe R
J Clin Invest; 2019 Mar; 129(6):2463-2479. PubMed ID: 30912767
[TBL] [Abstract][Full Text] [Related]
24. Analysis of the expression of HLA class I, proinflammatory cytokines and chemokines in primary tumors from patients with localized and metastatic renal cell carcinoma.
Romero JM; Aptsiauri N; Vazquez F; Cozar JM; Canton J; Cabrera T; Tallada M; Garrido F; Ruiz-Cabello F
Tissue Antigens; 2006 Oct; 68(4):303-10. PubMed ID: 17026465
[TBL] [Abstract][Full Text] [Related]
25. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis.
Turajlic S; Litchfield K; Xu H; Rosenthal R; McGranahan N; Reading JL; Wong YNS; Rowan A; Kanu N; Al Bakir M; Chambers T; Salgado R; Savas P; Loi S; Birkbak NJ; Sansregret L; Gore M; Larkin J; Quezada SA; Swanton C
Lancet Oncol; 2017 Aug; 18(8):1009-1021. PubMed ID: 28694034
[TBL] [Abstract][Full Text] [Related]
26. Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications.
Chen YP; Zhang Y; Lv JW; Li YQ; Wang YQ; He QM; Yang XJ; Sun Y; Mao YP; Yun JP; Liu N; Ma J
Theranostics; 2017; 7(14):3585-3594. PubMed ID: 28912897
[TBL] [Abstract][Full Text] [Related]
27. Spontaneous peripheral T-cell responses toward the tumor-associated antigen cyclin D1 in patients with clear cell renal cell carcinoma.
Dannenmann SR; Hermanns T; Bransi A; Matter C; von Boehmer L; Stevanovic S; Schraml P; Moch H; Knuth A; van den Broek M
Cancer Immunol Res; 2013 Nov; 1(5):288-95. PubMed ID: 24777966
[TBL] [Abstract][Full Text] [Related]
28. Immunoscoring by correlating MHC class II and TCR expression: high level immune functions represented by the KIRP dataset of TCGA.
Butler SN; Blanck G
Cell Tissue Res; 2016 Feb; 363(2):491-6. PubMed ID: 26293619
[TBL] [Abstract][Full Text] [Related]
29. Structure, expression and function of HLA-G in renal cell carcinoma.
Seliger B; Schlaf G
Semin Cancer Biol; 2007 Dec; 17(6):444-50. PubMed ID: 17707652
[TBL] [Abstract][Full Text] [Related]
30. Expression pattern of HLA class I antigens in renal cell carcinoma and primary cell line cultures: methodological implications for immunotherapy.
Hanak L; Slaby O; Lauerova L; Kren L; Nenutil R; Michalek J
Med Sci Monit; 2009 Dec; 15(12):CR638-43. PubMed ID: 19946235
[TBL] [Abstract][Full Text] [Related]
31. Progressive immune dysfunction with advancing disease stage in renal cell carcinoma.
Braun DA; Street K; Burke KP; Cookmeyer DL; Denize T; Pedersen CB; Gohil SH; Schindler N; Pomerance L; Hirsch L; Bakouny Z; Hou Y; Forman J; Huang T; Li S; Cui A; Keskin DB; Steinharter J; Bouchard G; Sun M; Pimenta EM; Xu W; Mahoney KM; McGregor BA; Hirsch MS; Chang SL; Livak KJ; McDermott DF; Shukla SA; Olsen LR; Signoretti S; Sharpe AH; Irizarry RA; Choueiri TK; Wu CJ
Cancer Cell; 2021 May; 39(5):632-648.e8. PubMed ID: 33711273
[TBL] [Abstract][Full Text] [Related]
32. High-dimensional Cytometry (ExCYT) and Mass Spectrometry of Myeloid Infiltrate in Clinically Localized Clear Cell Renal Cell Carcinoma Identifies Novel Potential Myeloid Targets for Immunotherapy.
Theodros D; Murter BM; Sidhom JW; Nirschl TR; Clark DJ; Chen L; Tam AJ; Blosser RL; Schwen ZR; Johnson MH; Pierorazio PM; Zhang H; Ganguly S; Pardoll DM; Zarif JC
Mol Cell Proteomics; 2020 Nov; 19(11):1850-1859. PubMed ID: 32737216
[TBL] [Abstract][Full Text] [Related]
33. Tumor Cell-Derived TGFβ1 Attenuates Antitumor Immune Activity of T Cells via Regulation of PD-1 mRNA.
Wu P; Geng B; Chen Q; Zhao E; Liu J; Sun C; Zha C; Shao Y; You B; Zhang W; Li L; Meng X; Cai J; Li X
Cancer Immunol Res; 2020 Dec; 8(12):1470-1484. PubMed ID: 32999004
[TBL] [Abstract][Full Text] [Related]
34. Extracting tumor tissue immune status from expression profiles: correlating renal cancer prognosis with tumor-associated immunome.
Teltsh O; Porgador A; Rubin E
Oncotarget; 2015 Oct; 6(32):33191-205. PubMed ID: 26384298
[TBL] [Abstract][Full Text] [Related]
35. Exploration of immune-related genes in high and low tumor mutation burden groups of chromophobe renal cell carcinoma.
Li L; Chen X; Hao L; Chen Q; Liu H; Zhou Q
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32662515
[TBL] [Abstract][Full Text] [Related]
36. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
[TBL] [Abstract][Full Text] [Related]
37. Mutanome and expression of immune response genes in microsatellite stable colon cancer.
Sanz-Pamplona R; Gil-Hoyos R; López-Doriga A; Alonso MH; Aussó S; Molleví DG; Santos C; Sanjuán X; Salazar R; Alemany R; Moreno V
Oncotarget; 2016 Apr; 7(14):17711-25. PubMed ID: 26871478
[TBL] [Abstract][Full Text] [Related]
38. Transcriptional Profiling Reveals Kidney Neutrophil Heterogeneity in Both Healthy People and ccRCC Patients.
Meng Y; Cai K; Zhao J; Huang K; Ma X; Song J; Liu Y
J Immunol Res; 2021; 2021():5598627. PubMed ID: 33791390
[TBL] [Abstract][Full Text] [Related]
39. Higher HLA class I expression in renal cell carcinoma than in autologous normal tissue.
Sáenz-López P; Gouttefangeas C; Hennenlotter J; Concha A; Maleno I; Ruiz-Cabello F; Cózar JM; Tallada M; Stenzl A; Rammensee HG; Garrido F; Cabrera T
Tissue Antigens; 2010 Feb; 75(2):110-8. PubMed ID: 19912575
[TBL] [Abstract][Full Text] [Related]
40. Expression and regulation of non-classical HLA-G in renal cell carcinoma.
Dunker K; Schlaf G; Bukur J; Altermann WW; Handke D; Seliger B
Tissue Antigens; 2008 Aug; 72(2):137-48. PubMed ID: 18721274
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
